PubMed Health⌕ Search

Biomedical subjects

James Hathcock

Publications and source records attributed to James Hathcock.

3 recordsLinked to original sources

Vascular biology-the role of tissue factor.

It is well established that tissue factor (TF) is abundantly present in various extravascular tissues, in the adventitia of blood vessels, and in atheroma. Thus, in the event of plaque rupture or damage to the blood vessel wall, TF is readily exposed to flowing blood, allowing it to form a complex with circulating factor VIIa (FVIIa) in order to activate factor X (FX) both directly, and indirectly via factor IX (FIX). Platelets quickly adhere to the injured site, facilitating localized thrombin formation and subsequent fibrin production. With each new layer of platelets and fibrin that adheres to the injured surface, the exposed TF on the vessel wall, along with the localized circulating factors IX (FIXa) and X (FXa) that it generates, becomes increasingly isolated from the events near the surface of the growing thrombus. The physical blanketing of an injured surface by platelets and fibrin in addition to the release of platelet tissue factor pathway inhibitor (TFPI), prevents FIXa and FXa from diffusing more than a few tens of microns away from the vessel wall, far short of the 3 mm thickness needed for occlusive thrombosis. Thus an alternative FXa-generating mechanism must be involved that allows for the formation of prothrombinase activity far away from the vessel wall near the front of a growing thrombus.

Alternative Splicing↗

Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein.

Tissue factor (TF) is an essential enzyme activator that forms a catalytic complex with FVII(a) and initiates coagulation by activating FIX and FX, ultimately resulting in thrombin formation. TF is found in adventitia of blood vessels and the lipid core of atherosclerotic plaques. In unstable coronary syndromes, plaque rupture initiates coagulation by exposing TF to blood. Biologically active TF has been detected in vessel walls and circulating blood. Elevated intravascular TF has been reported in diverse pro-thrombotic syndromes such as myocardial infarction, sepsis, anti-phospholipid syndrome and sickle-cell disease. It is unclear how TF circulates, although it may be present in pro-coagulant microparticles. We now report identification of a form of human TF generated by alternative splicing. Our studies indicate that alternatively spliced human tissue factor (asHTF) contains most of the extracellular domain of TF but lacks a transmembrane domain and terminates with a unique peptide sequence. asHTF is soluble, circulates in blood, exhibits pro-coagulant activity when exposed to phospholipids, and is incorporated into thrombi. We propose that binding of asHTF to the edge of thrombi contributes to thrombus growth by creating a surface that both initiates and propagates coagulation.

Alternative Splicing↗

Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity.

BACKGROUND: Several studies suggest a role for an increased circulating pool of tissue factor (TF) in atherothrombotic diseases. Furthermore, certain cardiovascular risk factors, such as diabetes, hyperlipemia, and smoking, are associated with a higher incidence of thrombotic complications. We hypothesized that the observed increased blood thrombogenicity (BT) observed in patients with type 2 diabetes mellitus may be mediated via an increased circulating tissue factor activity. We have extended our study to smokers and hyperlipidemic subjects. METHODS AND RESULTS: Poorly controlled patients with type 2 diabetes mellitus (n=36), smokers (n=10), and untreated hyperlipidemic subjects (n=10) were studied. Circulating TF was immunocaptured from plasma, relipidated, and quantified by factor Xa (FXa) generation in the presence of factor VIIa. BT was assessed as thrombus formation on the Badimon perfusion chamber. Patients with improvement in glycemic control showed a reduction in circulating TF (362+/-135 versus 243+/-74 pmol/L per min FXa, P=0.0001). A similar effect was observed in BT (15 445+/-1130 versus 12 072+/-596 microm/mm2, P=0.01). Two hours after smoking 2 cigarettes, TF was increased (217+/-72 versus 283+/-106 pmol/L per min FXa, P=0.003). Hyperlipidemic subjects showed higher TF (237+/-63 versus 195+/-44 pmol/L per min FXa, P=0.035) than healthy volunteers. CONCLUSIONS: These findings suggest that high levels of circulating TF may be the mechanism of action responsible for the increased thrombotic complications associated with the presence of these cardiovascular risk factors. These observations strongly emphasize the usefulness of the management of the patients based on their global risk assessment.

Cardiovascular Diseases↗